Rohin obtained a notice of acceptance of the application for the listing of acetic acid Abitron tablets.

Prostate cancer is one of the most common malignant tumors in men, and the incidence of prostate cancer in China has been on the rise in recent years.
Studies have shown that androgens play an important role in the development of prostate cancer, and that acetic acid abitron is a precursor drug that is rapidly converted into a bittron in the body, which is an select, irreversible steroid inhibitor of CYP17 (17 alpha-hydroxyase and C17,20-lysase) that blocks the synthesis of male hormones in testes, adrenastics, and tumors by inhibiting enzyme activity.
This product was first approved by the FDA on April 28, 2011 by Johnson and Johnson for the treatment of metastatic desopathic prostate cancer and newly diagnosed high-risk metastatic endocrine therapy sensitive prostate cancer, including non-endocrine therapy or endocrine therapy for up to 3 months.
was approved for listing in the EU in September 2011 and in China in 2015.
acetic acid acetic acid Abitorn tablet from MSN LABORATORIES PRIVATE LIMITED was approved for sale in the United States in July 2019.
November 2019, MSN LABORATORIES PRIVATELIMITED signed a Production/Licensing/Supply and Distribution Agreement with Hong Kong Rohingya, a subsidiary of the Company, and Hong Kong Rohingya or its affiliates obtained exclusive rights to import, register, promote and commercialize the products of Abitron tablets in Chinese mainland, The Hong Kong Special Administrative Region and the Macao Special Administrative Region.
according to IQVIA data, the global sales of acetic acid acetic acid abitor tablets in 2019 amounted to US$3.25 billion and the sales amount in China amounted to RMB1.13 billion. according to the
announcement, Abitron tablets acetate is the first overseas listed drug application introduced by Luoxin Pharmaceuticals through international cooperation in China, compared with local imitation development, with a short listing cycle, low cost and other advantages, reflecting Luo Xin's ability to enrich product pipelines and expand business through international cooperation, but also for the introduction of the company's follow-up projects to provide an important reference for the company and international enterprises to develop cooperation.
source: Rohingya Pharmaceuticals.